Clinical Trial: U31402-A-U103

Trial Status: Open
Disease Type: Lung
Trial ID U31402-A-U103
Sponsor ID Daiichi Sankyo

A Phase I Open-Label Study of Patritumab Deruxtecan (U3-1402) in Combination with Osimertinib in Subjects with Locally Advanced or Mets EGFR-Mutated NSCLC

1 Location


Fairfax Office

Learn More About This Trial

Other Relevant Trials
Trial ID NAV-1104
Sponsor ID Navire Pharma

Phase 1 Study of SHP2 Inhibitor BBP-398 in Combination with the Programmed Death Receptor-1 Blocking Antibody Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer with a KRAS Mutation

1 Location
Sponsor ID Arri Vent BioPharma

A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Activating EGFR or HER2 Mutations Including Exon 20 Insertion Mutations

1 Location